ProCE Banner Series

Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum

Live satellite symposium with a multidisciplinary panel covering the evolving role of immunotherapy in the management of intermediate HCC.

Not an official event of the 2024 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.

Who Should Attend

This educational program is intended for medical oncologists and other healthcare professionals who treat patients with hepatocellular carcinoma.

All Events

Immunotherapy in HCC: Improving Outcomes Across the Disease Continuum

Past Events




6:30 PM - 8:30 PM Central Time (CT)


Hilton Chicago, 720 S Michigan Ave, Chicago, Illinois 60605

7:00 PM - 8:30 PM Central Time (CT)



ProCE Banner Faculty
Richard S. Finn, MD

Department of Medicine
Division of Hematology/Oncology
UCLA David Geffen School of Medicine
Medical Director, Clinical Research Unit
Director, Signal Transduction and Therapeutics Program
University of California, Los Angeles
Los Angeles, California

ProCE Banner Faculty
Sarah B. White, MD, MS, FSIR, FCIRSE

Professor of Radiology and Surgical Oncology
Vice Chair, Radiology Research
Associate Dean/Assistant Provost, Faculty Affairs
Senior Medical Director, Programmatic Excellence
Department of Radiology, Division of Vascular & Interventional Radiology
Medical College of Wisconsin
Milwaukee, Wisconsin

ProCE Banner Faculty
Mark Yarchoan, MD

Associate Professor of Medical Oncology
Division of GI Malignancies
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland


Registration & Dinner - 6:30 PM - 7:00 PM CT

Immunotherapy-Based Combinations in Intermediate HCC (Eligible for TACE)

  • Clinical considerations and unmet medical need of improving on TACE
  • Adding systemic therapy to prior findings (LAUNCH)
    • Synergistic antitumor effects with lenvatinib + TACE
  • Rationale for the combination of anti-VEGF and ICI
  • Ongoing phase III studies

Immunotherapy-Based Combinations as Adjuvant Therapy for High-Risk HCC

  • Staging of high risk and unmet medical need
  • Ongoing phase III studies

Immunotherapy in Advanced/Metastatic HCC

  • Selecting among the combination regimens in HCC
  • Panel discussion:
    • Management of safety

Closing Remarks and Audience Question and Answer Session

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.


Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Hepatocellular Carcinoma (HCC).

Target Audience
This educational program is intended for medical oncologists and other healthcare professionals who treat patients with hepatocellular carcinoma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Describe the biological rationale for targeting immune checkpoints and VEGF or 2 different immunotherapies

  • Integrate clinical data and guideline recommendations on the use of systemic treatment approaches into practice for patients with resected/ablated or intermediate-stage HCC

  • Plan evidence-based and guideline-driven individualized care for patients with advanced or metastatic HCC

  • Identify patients with HCC who may benefit from ongoing clinical trials investigating ICI-based therapies


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


Provided by Clinical Care Options, LLC

Supported by an educational grant from AstraZeneca.